Biotechnology giant Amgen is selling the Japanese rights to up to 13 of its experimental drugs to Takeda Pharmaceutical of Japan in a deal that might bring Amgen more than $1 billion.
The deal, announced by the companies early Monday, is part of an effort by Amgen to trim expenses as it struggles with falling sales of its anemia drugs because of questions about their safety. It is also an effort by the company to help more quickly bring its experimental drugs to market without overloading its staff.
More at the NYT
No comments:
Post a Comment